Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PALMERI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 130.670
NA - Nord America 5.111
AS - Asia 2.526
SA - Sud America 320
AF - Africa 81
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
Totale 138.720
Salva come PNG Salva come JPEG
Nazione #
IE - Irlanda 127.731
US - Stati Uniti d'America 5.053
SG - Singapore 875
CN - Cina 682
RU - Federazione Russa 636
UA - Ucraina 502
IT - Italia 501
DE - Germania 367
FI - Finlandia 282
HK - Hong Kong 281
BR - Brasile 255
VN - Vietnam 210
PL - Polonia 155
GB - Regno Unito 148
JP - Giappone 139
FR - Francia 114
SE - Svezia 83
BD - Bangladesh 69
IN - India 61
KR - Corea 59
CI - Costa d'Avorio 32
RO - Romania 31
NL - Olanda 29
BE - Belgio 28
CA - Canada 23
IQ - Iraq 23
AR - Argentina 21
TR - Turchia 21
MX - Messico 20
ES - Italia 16
AT - Austria 15
ZA - Sudafrica 15
ID - Indonesia 13
UZ - Uzbekistan 11
PK - Pakistan 10
CL - Cile 9
PY - Paraguay 9
EU - Europa 8
MY - Malesia 8
CH - Svizzera 7
EG - Egitto 7
KE - Kenya 7
MA - Marocco 7
NP - Nepal 7
PH - Filippine 7
VE - Venezuela 7
CO - Colombia 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
EC - Ecuador 5
GR - Grecia 5
IR - Iran 5
JM - Giamaica 5
JO - Giordania 5
AL - Albania 4
AU - Australia 4
CZ - Repubblica Ceca 4
IL - Israele 4
TH - Thailandia 4
TN - Tunisia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
ET - Etiopia 3
LB - Libano 3
NG - Nigeria 3
PE - Perù 3
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
KG - Kirghizistan 2
OM - Oman 2
PR - Porto Rico 2
QA - Qatar 2
TT - Trinidad e Tobago 2
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
GA - Gabon 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
MK - Macedonia 1
MM - Myanmar 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
Totale 138.720
Salva come PNG Salva come JPEG
Città #
Dublin 127.730
Ashburn 690
Singapore 604
Fairfield 397
Chandler 345
Jacksonville 285
San Jose 272
Hong Kong 268
Woodbridge 251
Houston 224
Wilmington 206
Ann Arbor 181
Des Moines 154
Seattle 154
Zgierz 141
Tokyo 139
Cambridge 134
Frankfurt am Main 129
Beijing 124
Moscow 124
Medford 105
Santa Clara 99
Nanjing 91
Altamura 81
Princeton 73
Council Bluffs 68
Tulsa 65
Los Angeles 63
Palermo 62
Lauterbourg 60
Boardman 59
Ho Chi Minh City 59
Hanoi 50
Dearborn 49
Hefei 49
Lawrence 49
The Dalles 45
New York 44
Dallas 36
San Diego 36
Abidjan 32
Buffalo 32
Shenyang 29
Brussels 28
Seongnam 27
Helsinki 26
Nanchang 26
Changsha 24
Chicago 24
Hebei 22
Ludwigshafen am Rhein 22
São Paulo 22
Milan 20
Jinan 18
Amsterdam 17
Columbus 17
Tianjin 17
Verona 17
Guangzhou 16
Rome 14
Da Nang 13
City of London 12
London 12
San Mateo 12
Zhengzhou 12
Cardiff 11
Chennai 11
Nuremberg 11
Jiaxing 10
Kunming 10
Phoenix 10
Washington 10
Atlanta 9
Belo Horizonte 9
Falls Church 9
Johannesburg 9
Montreal 9
Ningbo 9
San Paolo di Civitate 9
Tashkent 9
Warsaw 9
Brooklyn 8
Kumar 8
Rio de Janeiro 8
Taiyuan 8
Auburn Hills 7
Haiphong 7
Kilburn 7
Nairobi 7
Orem 7
Baghdad 6
Can Tho 6
Denver 6
Dongguan 6
Istanbul 6
Poplar 6
Santiago 6
Amman 5
Ankara 5
Bologna 5
Totale 134.584
Salva come PNG Salva come JPEG
Nome #
Analisi della frequenza del polimorfismo 1249-1250insACAA del gene TGF-beta2 in un gruppo di pazienti affette da carcinoma della mammella. 127.901
“Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma” 281
“Cytokine gene polymorphisms and breast cancer susceptibility” 251
“Weekly docetaxel and gemcitabine as first line treatment for metastatic breast cancer: results of a multicenter phase II study” 244
“Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5- fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer” 226
“A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer” 225
"Weekly docetaxel in the treatment of metastatic breast cancer" 218
“Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site” 214
Prognostic value of vascular endothelial growth factor (VEGF) and D-Dimer (DD) levels in cancer patients 213
“High efficacy of the CHOP + Rituximab association in a case of primary rectal non Hodgkin lymphoma (NHL)” 210
"Should cirrhosis change our attitude towards treating non-hepatic cancer?" 204
“Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and Intravenous Bolus 5-Fluorouracil for Metastatic Colorectal Cancer: Pooled Analysis of Two Consecutive Southern Italy Cooperative Oncology Group Trials” 198
F3 the advantage of ultrasound-guided FNA of pleura in the diagnosis of the malignant pleural effusion 198
"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet" 197
“Progression-free survival as an end-point in clinical trials of biotherapeutic agents” 194
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience 189
“Analysis of interleukin 10 (IL-10)-1082 G/A single nucleotide polymorphism (SNP) genotypes in breast cancer (BC) patients (pts) and in >95 years old cancer free women" 188
“Serum HER-2/neu (s-HER2) levels evaluation in breast cancer (BC) patients (PTS)” 188
Weekly docetaxel (wDOC) for the treatment of metastatic breast cancer (MBC): A literature based meta-analysis 188
“Weekly regimen of cisplatin, epirubicin, 5-Fluorouracil and folinic acid with G-CSF is active in advanced gastroesophageal (GE) and gastric (G) cancer: a phase II study” 186
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? 186
“Clinical surrogate end-points” 182
“Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with metastatic (M) breast cancer (BC): results of an observational study” 181
“Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer:the IGCS-COL multicentre, randomised, phase III study” 176
“Analysis of serum HER-2/neu levels (S-HER2) in breast cancer (BC) patients (pts)” 176
GASTRIC CANCER (GC) ADJUVANT (A) CHEMOTHERAPY (CT): A LITERATURE BASED META-ANALYSIS (MA) 176
“Long-Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response ( 173
Incidence of different KRAS mutation in non-small cell lung cancer (NSCLC) patients, TAILOR STUDY 171
"Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with early (E) breast cancer (BC)” 170
”Biweekly oxaliplatin combined with ral Capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study” 169
“Results of a phase II study of a weekly regimen of cisplatin (CDDP),epirubicin (EPI), fluorouracil (5FU) and folinic acid (FA) with G-CSF in gastroesophageal (GE) and gastric (G) cancer” 168
“Dose-Dense Primary Chemotherapy, as Part of Multidisciplinary Treatment, for Inoperable Stage III B Breast Cancer - Long-Term Results of a Phase II Trial” 168
"Weekly regimen of cisplatin (CDDP),epirubicin (EPI), fluorouracil (5FU) and folinic acid (FA) with G-CSF is active in advanced gastroesophageal (GE) and gastric (G) cancer: results of a phase II study” 162
“Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: A multicenter phase II trial of the Southern Italy Cooperative Oncology Group”. 159
“Oxaliplatin plus high dose folinic acid and 5-fluoruracil i.v. bolus (OXAFAFU) versus irinotecan plus high dose folinic acid and 5-fluoruracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group trial 0103” 149
“Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium” 149
The effectiveness of the topical use of 0,2% glyceryl trinitrate to decrease post –hemorrhoidectomy pain and to improve wounds healing. 147
“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)” 142
“Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey” 141
“Final results of a phase II trial of a weekly (W) poly-chemotherapy (CT) with cisplatin (CDDP), epirubicin (EPI), fluorouracil (5FU), folinic acid (FA) and G-CSF for the treatment of gastroesophageal (GE) and gastric (G) cancer (C)” 139
L’anemia nel paziente oncologico 136
“Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401”. 136
“Role of loco-regional treatments for patients with breast cancer liver metastases” 133
“Breast conservation therapy as a safe and effective alternative to mastectomy for selected T4 patients treated with primary chemotherapy as part of multimodality approach” 130
“Biweekly oxaliplatin plus capecitabine (OXXEL) versus oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus (OXAFAFU) in metastatic colorectal carcinoma (MCC): safety interim analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial” 129
“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience” 127
"Unknown primary tumors" 127
“Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small cell lung cancer: a phase III randomized trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)” 126
“Cisplatin (P)- including triplets versus P-free doublets in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): SICOG 0101 randomized trial” 125
“Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study” 125
“Carcinoma mammario metastatico: quali farmaci in seconda linea?” 124
“The European Medicines Agency (EMEA) guideline on oncology drug development” 124
“Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials”. 117
“Impact of pathological response on survival in stage IIIB T4 LABC patients:long-term outcome of an Italian multicentric study” 116
“Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the Southern Italy Cooperative Oncology Group (SICOG) experience” 116
“Erlotinib” 115
“Capecitabine or folinic acid/fluorouracil i.v bolus plus eloxatin evaluation (COFFE trial) in metastatic colorectal carcinoma (MCRC): final results of the Southern Italy Cooperative Oncology Group (SICOG) 0401” 115
“OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial” 115
“OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis” 115
“Long-term effect in outcomes of intensified primary chemotherapy in poor prognosis LABC T4 patients: results of a multicenter Italian study” 114
“Randomized comparison of capecitabine versus fluorouracil/leucovorin in combination with oxaliplatin in metastatic colorectal cancer patients: Southern Italy Cooperative Oncology Group trial 0401” 113
“Dose-dense chemotherapy and the onset of anemia: new insights” 111
“Intensified primary chemotherapy improved the outcome in poorer prognosis LABC T4 patients: results of a multicentric Italian study” 110
“Weekly docetaxel (DOC) and Gemcitabine (GEM) as first line treatment for metastatic breast cancer (MBC): results of a multicenter phase II study” 109
“Role of biomarkers in the regulatory process” 109
”L’associazione di gemcitabina e docetaxel nel trattamento del carcinoma mammario metastatico” 108
“Cisplatin (P)-including triplets versus P-free doublets in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): final results of the SICOG 0101 randomized trial” 104
“Biweekly docetaxel (T) and gemcitabine (G) followed by oral vinorelbine as first line treatment of metastatic breast cancer: preliminary results” 103
“Preliminary results of G > GVIELC: a phase III trial of gemcitabine associated to vindesine or gemcitabine alone in elderly or poor performance patients with advanced non-small cell lung cancer (NSCLC)” 98
“I tumori di origine sconosciuta” 87
“Il rapporto medico-paziente in Oncologia Medica”All Oncology 73
Totale 138.787
Salva come PNG Salva come JPEG
Categoria #
all - tutte 163.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 163.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202183 0 0 0 0 0 0 0 0 0 0 0 83
2021/2022673 22 183 5 15 27 26 26 35 90 86 22 136
2022/20231.066 122 200 12 92 134 160 117 74 93 7 38 17
2023/2024478 29 74 18 87 36 68 44 74 4 6 3 35
2024/20251.132 17 65 96 121 15 41 67 69 82 110 159 290
2025/20264.061 254 113 200 252 365 564 527 396 444 724 126 96
Totale 138.787